Revlimid is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma

Subtype:

Mantle Cell Lymphoma (MCL)

License:

EMA

Class:

Immunomodulatory agent

R/R

SmPC: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf 

  1. Approved Labelling

    Revlimid is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma

  2. Treatment Regimen

    Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies.
    The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles. Dosing is continued or modified based upon clinical and laboratory findings.

  3. AE/Warnings

    Please see section 4.4 of SmPC.

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.